Summit Therapeutics

ASCO Summit: Ivonescimab's China Lung Data Shows Promise, But Global Validation Remains Key

lung · 8 min

Summit Therapeutics' ivonescimab demonstrated a significant survival benefit in a Chinese lung cancer trial presented at ASCO, yet analysts caution that replicating these results in a broader, global population is crucial for its market potential against established therapies like Keytruda.

Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation

Food and Drug Administration · sickle cell disease · 5 min

Fulcrum Therapeutics' stock experienced a significant 54% drop following the discontinuation of its sickle cell disease drug, citing regulatory hurdles. This event highlights potential challenges in clinical trial design for the indication.

ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study

8 min

Structured plan for ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study

Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus

Ebola · 6 min

Biotech stocks showed mixed performance as Moderna advanced its Ebola vaccine efforts and Summit Therapeutics saw a surge on Phase 3 data. Meanwhile, Alignment Healthcare faced a downgrade, and Iovance Biotherapeutics remains a subject of analyst debate.

#ASCO26 Insights: Head and Neck Cancer Developments

head and neck cancer · 3 min

This article reviews significant head and neck cancer findings from ASCO26, focusing on insights from J&J, Corbus, Summit, Akero, and Bicara. Discover the implications for pharmaceutical stakeholders.